Answers are grounded in this paper and cite their sources.
This case report details osteonecrosis linked to lenvatinib in a patient with hcc, highlighting management challenges.
Lenvatinib is associated with adverse effects such as osteonecrosis of the jaw (ONJ) in patients undergoing treatment for malignancies. This case report presents a 56-year-old male with hepatocellular carcinoma undergoing lenvatinib therapy who presented with ONJ with significant bone destruction surrounding mandibular implants. Bone loss was extensive and thus treated with sequestrectomy and curettage. Although healing was observed initially, an additional sequestrum was observed at the 3-month follow-up. This case highlights the potential link of lenvatinib associated ONJ. Further research is required to clarify the mechanisms underlying lenvatinib-induced ONJ and to improve management strategies.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: